{"id":"ranitidine","rwe":[],"_fda":{"id":"c47f1d10-c4d9-5df4-84e8-55956b47568b","set_id":"00df8a42-296f-80dd-98af-ee8b30eb38cc","openfda":{"unii":["BK76465IHM"],"route":["ORAL"],"rxcui":["198191"],"spl_id":["c47f1d10-c4d9-5df4-84e8-55956b47568b"],"brand_name":["Ranitidine"],"spl_set_id":["00df8a42-296f-80dd-98af-ee8b30eb38cc"],"package_ndc":["55111-404-34","55111-404-32","55111-404-36","55111-404-50","55111-404-61","55111-404-55","55111-404-62","55111-404-90","55111-404-02","55111-404-65","55111-404-17","55111-404-24","55111-404-38","55111-404-40"],"product_ndc":["55111-404"],"generic_name":["RANITIDINE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["RANITIDINE HYDROCHLORIDE"],"manufacturer_name":["Dr. Reddy's Laboratories Limited"],"application_number":["ANDA078192"],"is_original_packager":[true]},"purpose":["Purpose Acid reducer"],"version":"12","stop_use":["Stop use and ask doctor if your heartburn continues or worsens you need to take this product for more than 14 days"],"warnings":["Warnings Allergy alert: Do not use if you are allergic to ranitidine or other acid reducers Do not use if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools.These may be signs of a serious condition. See your doctor. with other acid reducers Ask a doctor before use if you have had heartburn over 3 months. This may be a sign of a more serious condition. heartburn with lightheadedness, sweating or dizziness chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness frequent chest pain frequent wheezing, particularly with heartburn unexplained weight loss nausea or vomiting stomach pain kidney disease Ask a doctor or pharmacist before use if you are • taking a prescription drug. Acid reducers may interact with certain prescription drugs. Stop use and ask doctor if your heartburn continues or worsens you need to take this product for more than 14 days If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222)."],"questions":["Questions? Call 1-888-375-3784 Read the directions and warnings before use. Keep the carton. It contains important information including tips for managing heartburn."],"ask_doctor":["Ask a doctor before use if you have had heartburn over 3 months. This may be a sign of a more serious condition. heartburn with lightheadedness, sweating or dizziness chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness frequent chest pain frequent wheezing, particularly with heartburn unexplained weight loss nausea or vomiting stomach pain kidney disease"],"do_not_use":["Do not use if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools.These may be signs of a serious condition. See your doctor. with other acid reducers"],"effective_time":"20250523","active_ingredient":["Active ingredient (in each tablet) Ranitidine 150 mg (as ranitidine hydrochloride USP, 168 mg)"],"inactive_ingredient":["Inactive ingredients FD&C red #40 aluminum lake, hypromellose, iron oxide black, magnesium stearate, microcrystalline cellulose, polyethylene glycol, titanium dioxide."],"indications_and_usage":["Use(s) relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages"],"spl_unclassified_section":["Other information do not use if printed foil under bottle cap is open or torn store at 20°-25°C (68°-77°F) avoid excessive heat or humidity protect from light this product is sodium and sugar free","Tips for managing heartburn Do not lie flat or bend over soon after eating Do not eat late at night, or just before bedtime Certain foods or drinks are more likely to cause heartburn, such as rich, spicy, fatty, and fried foods, chocolate, caffeine, alcohol, and even some fruits and vegetables. Eat slowly and do not eat beig meals If you are overweight, lose weight If you smoke, quit smoking Raise the head of your bed Wear loose fitting clothing around your stomach. Revised: 03/20"],"dosage_and_administration":["Directions adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor"],"spl_product_data_elements":["Ranitidine Ranitidine Ranitidine Hydrochloride RANITIDINE FD&C RED NO. 40 HYPROMELLOSE 2910 (6 MPA.S) FERROSOFERRIC OXIDE magnesium stearate cellulose, microcrystalline POLYETHYLENE GLYCOL 400 titanium dioxide R150 containercarton container blistercarton"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding, ask a health professional before use."],"keep_out_of_reach_of_children":["Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222)."],"package_label_principal_display_panel":["PACKAGE LABEL PRINCIPAL DISPLAY PANEL Container Label: Dr.Reddy's NDC 55111-404-34 Maximum Strength Ranitidine Tablets USP,150 mg ACID REDUCER PREVENTS & RELIEVES HEARTBURN associated with acid indigestion and sour stomach 24 Tablets(24 doses)","Container Carton Label: Dr.Reddy's NDC 55111-404-34 Compare to the active ingredient in Zantact 150 ® Tablets* Maximum Strength Ranitidine Tablets USP,150 mg ACID REDUCER PREVENTS & RELIEVES heartburn associated with acid indigestion and sour stomach 24 Tablets(24 doses)","Blister Carton Label: Dr.Reddy's NDC 55111-404-24 Maximum Strength Ranitidine Tablets USP,150 mg ACID REDUCER PREVENTS & RELIEVES HEARTBURN associated with acid indigestion and sour stomach 24 Tablets(24 doses)"]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"BREAST CANCER","source":"FDA FAERS","actionTaken":"29411 reports"},{"date":"","signal":"PROSTATE CANCER","source":"FDA FAERS","actionTaken":"26446 reports"},{"date":"","signal":"COLORECTAL CANCER","source":"FDA FAERS","actionTaken":"20720 reports"},{"date":"","signal":"BLADDER CANCER","source":"FDA FAERS","actionTaken":"19207 reports"},{"date":"","signal":"RENAL CANCER","source":"FDA FAERS","actionTaken":"19035 reports"},{"date":"","signal":"OESOPHAGEAL CARCINOMA","source":"FDA FAERS","actionTaken":"11067 reports"},{"date":"","signal":"INCORRECT DOSE ADMINISTERED","source":"FDA FAERS","actionTaken":"9738 reports"},{"date":"","signal":"HEPATIC CANCER","source":"FDA FAERS","actionTaken":"8834 reports"},{"date":"","signal":"GASTRIC CANCER","source":"FDA FAERS","actionTaken":"8743 reports"},{"date":"","signal":"PANCREATIC CARCINOMA","source":"FDA FAERS","actionTaken":"8037 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea/Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal Discomfort/Pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Disease of liver","Kidney disease","Malignant tumor of stomach","Porphyria"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Hepatocellular, Cholestatic, or Mixed Hepatitis","drugRate":"","severity":"serious"},{"effect":"Hepatic Failure","drugRate":"","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"","severity":"serious"},{"effect":"Aplastic Anemia","drugRate":"","severity":"serious"},{"effect":"Acquired Immune Hemolytic Anemia","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Acute Interstitial Nephritis","drugRate":"","severity":"serious"},{"effect":"Pancreatitis","drugRate":"","severity":"serious"},{"effect":"Arrhythmias (Tachycardia, Bradycardia, AV Block, PVBs)","drugRate":"","severity":"serious"},{"effect":"Mental Confusion, Agitation, Depression, Hallucinations","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT02170792","NCT01332630","NCT00405119","NCT03610217","NCT00590928","NCT02441894","NCT01908257","NCT04397445","NCT02123498","NCT01392755","NCT00247130","NCT03518463","NCT02441673","NCT00702871","NCT05077111","NCT02258815","NCT01411410","NCT01538797","NCT02197143","NCT02169856","NCT00633412","NCT02172417","NCT03541408","NCT01734759","NCT02999633","NCT01261546","NCT05991466","NCT03011463","NCT00633672","NCT01737840","NCT01209455","NCT01042704","NCT01287520","NCT01601522","NCT01976078","NCT03140033","NCT02555852","NCT02733640","NCT01726452","NCT03619408","NCT02360696","NCT02700087","NCT00855660","NCT02878512","NCT03050866","NCT03920306","NCT02205489","NCT01264328","NCT04294459","NCT02655458"],"aliases":["Zantac"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ranitidine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:07:23.866620+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:07:29.636831+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:07:22.571064+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ranitidine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:07:29.943733+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:21.326780+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:21.326812+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:07:31.475042+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H2 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:30.997819+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2110372/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:30.653259+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA078192","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:21.326816+00:00"}},"allNames":"zantac","offLabel":[],"timeline":[],"aiSummary":"Ranitidine (Zantac) was once the world\\","brandName":"Zantac","companyId":"gsk","ecosystem":[],"mechanism":{"target":"Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor","novelty":"","modality":"Small molecule","drugClass":"H2 receptor antagonist","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:07:32.910489+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"companyName":"GSK (originally Glaxo)","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"ranitidine","indications":{"approved":[{"name":"Duodenal Ulcer due to H. Pylori","diseaseId":"duodenal-ulcer-due-to-h.-pylori","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Duodenal ulcer disease","diseaseId":"duodenal-ulcer-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erosive esophagitis","diseaseId":"erosive-esophagitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastric Hypersecretory Conditions","diseaseId":"gastric-hypersecretory-conditions","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastric ulcer","diseaseId":"gastric-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastroesophageal reflux disease","diseaseId":"gastroesophageal-reflux-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Heartburn","diseaseId":"heartburn","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Indigestion","diseaseId":"indigestion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Maintenance of Healing Gastric Ulcer","diseaseId":"maintenance-of-healing-gastric-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Zollinger-Ellison syndrome","diseaseId":"zollinger-ellison-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02170792","phase":"Phase 1","title":"Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 50 or 200 mg BIBR 1048 MS Film-coated Tablet Over 2 Days With and Without Coadministration of Ranitidine to Healthy Subjects. Three Grou","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":30,"indication":"Healthy","completionDate":""},{"nctId":"NCT01332630","phase":"Phase 2","title":"A Phase 2 Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":24,"indication":"Breast Cancer","completionDate":"2017-04-14"},{"nctId":"NCT00405119","phase":"Phase 2","title":"A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Sub","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":92,"indication":"Gastroesophageal Reflux Disease, Reflux, Gastroesophageal","completionDate":"2007-03"},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","isPivotal":false,"enrollment":400,"indication":"Scleroderma, Systemic, Sclerosis, Systemic","completionDate":"2021-10"},{"nctId":"NCT00590928","phase":"Phase 4","title":"Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study.","status":"COMPLETED","sponsor":"Medical University of Vienna","isPivotal":false,"enrollment":75,"indication":"Critically Ill Patients, Indication for Stress Ulcer Prophylaxis","completionDate":"2006-06"},{"nctId":"NCT02441894","phase":"Phase 4","title":"Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":21,"indication":"Prostate Cancer","completionDate":"2016-11"},{"nctId":"NCT01908257","phase":"Phase 1","title":"A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Effects of Ranitidine on the Pharmacokinetics of Lesinurad in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","isPivotal":false,"enrollment":16,"indication":"Healthy","completionDate":"2013-11"},{"nctId":"NCT04397445","phase":"Phase 1","title":"Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","isPivotal":false,"enrollment":18,"indication":"Ranitidine Adverse Reaction, Pharmacokinetics","completionDate":"2020-07-01"},{"nctId":"NCT02123498","phase":"Phase 4","title":"The Study of the Diagnosis of Eustachian Tube Dysfunction (ETD): Identifying the Relationship of Ear Fullness to Laryngopharyngeal Reflux (LPR)","status":"WITHDRAWN","sponsor":"Loma Linda University","isPivotal":false,"enrollment":0,"indication":"Eustachian Tube Dysfunction, Laryngopharyngeal Reflux","completionDate":""},{"nctId":"NCT01392755","phase":"Phase 1","title":"A Study to Evaluate the Effects of Two Different Meal Types, Omeprazole and Ranitidine on Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Subjects","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":32,"indication":"Healthy Volunteer","completionDate":"2011-09"},{"nctId":"NCT00247130","phase":"Phase 4","title":"A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Pept","status":"WITHDRAWN","sponsor":"Keio University","isPivotal":false,"enrollment":0,"indication":"Peptic Ulcers","completionDate":"2007-07"},{"nctId":"NCT03518463","phase":"NA","title":"Enhanced Recovery After Surgery Versus Standard Recovery for Emergency Caesarean Deliveries at Mbarara Hospital, Uganda: A Randomized Control Trial","status":"COMPLETED","sponsor":"Mbarara University of Science and Technology","isPivotal":false,"enrollment":160,"indication":"Pregnancy Related","completionDate":"2017-11-27"},{"nctId":"NCT02441673","phase":"Phase 2","title":"Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block","status":"UNKNOWN","sponsor":"Lagos State Health Service Commission","isPivotal":false,"enrollment":130,"indication":"Post Anaesthetic Shivering","completionDate":"2019-06"},{"nctId":"NCT00702871","phase":"Phase 4","title":"A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study","status":"COMPLETED","sponsor":"Maulana Azad Medical College","isPivotal":false,"enrollment":50,"indication":"Ventilator Associated Pneumonia, Etiological Organisms","completionDate":"2006-04"},{"nctId":"NCT05077111","phase":"Phase 4","title":"A Comparative Study Between Thoracic Epidural Anesthesia in Non-Intubated Video-Assisted Thoracoscopes and the Conventional General Anesthesia With One Lung Ventilation","status":"UNKNOWN","sponsor":"Mohamed Reda Ashour","isPivotal":false,"enrollment":40,"indication":"Pleural Effusion, Malignant, Pleural Mesothelioma","completionDate":"2021-10-15"},{"nctId":"NCT02258815","phase":"Phase 2","title":"Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"University Children's Hospital Tuebingen","isPivotal":false,"enrollment":35,"indication":"Neuroblastoma Recurrent","completionDate":"2022-12"},{"nctId":"NCT01411410","phase":"Phase 1","title":"A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3΄-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":55,"indication":"Neoplasms","completionDate":"2015-06-29"},{"nctId":"NCT01538797","phase":"Phase 1","title":"YF476: Effects of a Single Dose at 3 Dose Levels on 24-hour Ambulatory Gastric pH Compared With Placebo and Ranitidine in Healthy Volunteers","status":"COMPLETED","sponsor":"Trio Medicines Ltd.","isPivotal":false,"enrollment":22,"indication":"Reflux Oesophagitis","completionDate":"1996-08"},{"nctId":"NCT02197143","phase":"Phase 4","title":"A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain: A Double-Blind, Randomized, Controlled Trial","status":"COMPLETED","sponsor":"Pamukkale University","isPivotal":false,"enrollment":286,"indication":"Dyspepsia","completionDate":"2014-07"},{"nctId":"NCT02169856","phase":"NA","title":"A Randomized Controlled Trial: Role of EFTs (Emotional Freedom Techniques) in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy.","status":"COMPLETED","sponsor":"Benazir Bhutto Hospital, Rawalpindi","isPivotal":false,"enrollment":50,"indication":"Postoperative Nausea and Vomiting","completionDate":"2014-02"},{"nctId":"NCT00633412","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"enrollment":400,"indication":"NSAID Associated Gastric Ulcers","completionDate":"2003-03"},{"nctId":"NCT02172417","phase":"Phase 1","title":"The Effect of Concomitant Cimetidine p.o. 400 mg t.i.d. and p.o. Ranitidine 300 mg Once Daily on Single Dose Pharmacokinetics of Tiotropium (14.4 µg) Given Intravenously Over 15 Minutes in Healthy Mal","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":18,"indication":"Healthy","completionDate":""},{"nctId":"NCT03541408","phase":"NA","title":"A Randomized, Controlled Trial Reviewing the Effectiveness of a Preventative Delirium Protocol in Elderly Patients While Analyzing Its Consequential Effects on Awareness, PONV, and/or Pain Control","status":"COMPLETED","sponsor":"Rush University Medical Center","isPivotal":false,"enrollment":263,"indication":"Delirium","completionDate":"2021-04-01"},{"nctId":"NCT01734759","phase":"Phase 1","title":"Influence of Medication Palatability on Prescribing Habits of Pediatric Prescribers","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":50,"indication":"Healthy","completionDate":"2013-01"},{"nctId":"NCT02999633","phase":"Phase 2","title":"Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-","status":"TERMINATED","sponsor":"Sanofi","isPivotal":false,"enrollment":14,"indication":"T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia","completionDate":"2017-11-14"},{"nctId":"NCT01261546","phase":"Phase 2","title":"MULTICENTRIC, PHASE II, CLINICAL TRIAL CORTICOIDS FOR EMPYEMA AND PLEURAL EFFUSION IN CHILDREN","status":"COMPLETED","sponsor":"Hospital Infanta Sofia","isPivotal":false,"enrollment":60,"indication":"Parapneumonic Pleural Effusion, Empyema","completionDate":"2015-05"},{"nctId":"NCT05991466","phase":"Phase 4","title":"The Effect of Dexmedetomidine on the Quality of Recovery in Parturients Undergoing Elective Caesarean Sections: a Randomized Comparative Study","status":"COMPLETED","sponsor":"Cairo University","isPivotal":false,"enrollment":141,"indication":"The Quality of Recovery (ObsQOR-11)","completionDate":"2022-12-31"},{"nctId":"NCT03011463","phase":"Phase 1","title":"Pharmacokinetic Interaction Between Trospium Chloride After Intravenous (2 mg) and Oral Administration (30 mg) With Ranitidine (300 mg p.o.) as an Inhibitor of OCT1 and With Clarithromycin (500 mg p.o","status":"COMPLETED","sponsor":"Dr. R. Pfleger Chemische Fabrik GmbH","isPivotal":false,"enrollment":24,"indication":"Pharmacokinetics, Inhibition Enzyme","completionDate":"2017-03"},{"nctId":"NCT00633672","phase":"Phase 3","title":"A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is ","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"enrollment":400,"indication":"NSAID Associated Gastric Ulcers","completionDate":"2003-10"},{"nctId":"NCT01737840","phase":"Phase 4","title":"Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial.","status":"COMPLETED","sponsor":"Akdeniz University","isPivotal":false,"enrollment":66,"indication":"Dyspepsia","completionDate":"2013-01"},{"nctId":"NCT01209455","phase":"NA","title":"Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects","status":"COMPLETED","sponsor":"University of Edinburgh","isPivotal":false,"enrollment":24,"indication":"Poisoning","completionDate":"2011-07-15"},{"nctId":"NCT01042704","phase":"Phase 1","title":"Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Robert Redner, MD","isPivotal":false,"enrollment":29,"indication":"Myeloma","completionDate":"2015-03"},{"nctId":"NCT01287520","phase":"Phase 1","title":"Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":41,"indication":"Advanced Cancer","completionDate":"2011-04"},{"nctId":"NCT01601522","phase":"Phase 2","title":"Peanut Allergy Oral Immunotherapy Desensitization","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","isPivotal":false,"enrollment":43,"indication":"Peanut Allergy","completionDate":"2021-09"},{"nctId":"NCT01976078","phase":"N/A","title":"Ontogeny of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","isPivotal":false,"enrollment":45,"indication":"Pharmacokinetics, Voriconazole","completionDate":"2015-04-22"},{"nctId":"NCT03140033","phase":"Phase 2","title":"Sublingual Misoprostol Versus Placebo to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Study","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","isPivotal":false,"enrollment":158,"indication":"Hemorrhage Postpartum","completionDate":"2017-05"},{"nctId":"NCT02555852","phase":"N/A","title":"Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","isPivotal":false,"enrollment":4238504,"indication":"Gastroesophageal Reflux Disease (GERD), Community-acquired Pneumonia","completionDate":"2012-02"},{"nctId":"NCT02733640","phase":"NA","title":"","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","isPivotal":false,"enrollment":42,"indication":"Antiplatelet Effect","completionDate":"2015-05"},{"nctId":"NCT01726452","phase":"Phase 3","title":"Neo-AEGIS (NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (Modified MAGIC ","status":"COMPLETED","sponsor":"Cancer Trials Ireland","isPivotal":true,"enrollment":377,"indication":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction","completionDate":"2022-08-04"},{"nctId":"NCT03619408","phase":"N/A","title":"Management of Esophagitis Following Repair of Esophageal Atresia","status":"UNKNOWN","sponsor":"Boston Children's Hospital","isPivotal":false,"enrollment":50,"indication":"Esophageal Atresia, Esophagitis","completionDate":"2025-07"},{"nctId":"NCT02360696","phase":"N/A","title":"Predictors of Clinical Response to Montelukast in Children With Functional Dyspepsia","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","isPivotal":false,"enrollment":18,"indication":"Eosinophilia, Dyspepsia","completionDate":"2016-08"},{"nctId":"NCT02700087","phase":"NA","title":"In Infants With Symptoms of Tracheomalacia or Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms? A Randomized, Controlled Trial","status":"WITHDRAWN","sponsor":"Stanford University","isPivotal":false,"enrollment":0,"indication":"Laryngomalacia, Acid Reflux","completionDate":"2017-02"},{"nctId":"NCT00855660","phase":"Phase 1","title":"Investigation of the Effect of Riociguat, Administered as 2.5 mg IR-tablets TID Over 14 Days, on Bone Metabolism in a Randomized, Placebo-controlled, Double-blind, 2-fold Cross-over Design in Healthy ","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":17,"indication":"Pharmacology, Clinical","completionDate":"2010-07"},{"nctId":"NCT02878512","phase":"Phase 4","title":"Comparative Evaluation of General Anesthesia (SEA) Using 0.5% Bupivacaine and Segmental Epidural Anesthesia (GA) for Percutaneous Nephro Lithotomy - A Retrospective Analysis","status":"COMPLETED","sponsor":"Maharashtra University of Health Sciences","isPivotal":false,"enrollment":60,"indication":"Success Rate Under Segmental Epidural, Post Operative Pain","completionDate":"2010-12"},{"nctId":"NCT03050866","phase":"Phase 2","title":"A Single Arm Phase 2 Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","status":"UNKNOWN","sponsor":"Erasmus Medical Center","isPivotal":false,"enrollment":140,"indication":"Circulating Tumor Cell, Metastatic Prostate Cancer","completionDate":"2022-08-19"},{"nctId":"NCT03920306","phase":"Phase 4","title":"A Prospective Evaluation of Non-Operative Treatments for Gastrocutaneous Fistulae in Children","status":"UNKNOWN","sponsor":"University of British Columbia","isPivotal":false,"enrollment":100,"indication":"Gastrocutaneous Fistula, Gastrostomy Complications","completionDate":"2023-10-01"},{"nctId":"NCT02205489","phase":"Phase 4","title":"Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRA","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":58,"indication":"Relapsing-remitting Multiple Sclerosis","completionDate":"2016-04"},{"nctId":"NCT01264328","phase":"Phase 2","title":"\"Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer\"","status":"COMPLETED","sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","isPivotal":false,"enrollment":40,"indication":"Head and Neck Cancer","completionDate":"2014-09-29"},{"nctId":"NCT04294459","phase":"Phase 1","title":"A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab (SAR650984) in Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"Sanofi","isPivotal":false,"enrollment":23,"indication":"Immune System Disorder","completionDate":"2022-05-02"},{"nctId":"NCT02655458","phase":"Phase 1","title":"Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma","status":"COMPLETED","sponsor":"Hearn Jay Cho","isPivotal":false,"enrollment":15,"indication":"Multiple Myeloma","completionDate":"2017-07-13"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Once or twice daily","formulation":"Tablet, Liquid, Injectable"},"crossReferences":{"chemblId":"CHEMBL2110372"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":6518,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"firstApprovalDate":"1983-06-01","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-11-29T00:00:00.000Z","mah":"DR REDDYS LABS LTD","brand_name_local":null,"application_number":"ANDA075742"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-03-20T00:00:00.000Z","mah":"AMNEAL PHARMS NY","brand_name_local":null,"application_number":"ANDA077824"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-01-18T00:00:00.000Z","mah":"DR REDDYS LABS LTD","brand_name_local":null,"application_number":"ANDA078192"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-08-20T00:00:00.000Z","mah":"GRANULES","brand_name_local":null,"application_number":"ANDA210243"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-08-07T00:00:00.000Z","mah":"VKT PHARMA","brand_name_local":null,"application_number":"ANDA211289"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:07:32.910489+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}